

CONTENTS

TITLE	PAGE NO.
CHAPTER 1: INTRODUCTION	1
CHAPTER 2: AIMS AND OBJECTIVES	19
CHAPTER 3: IMPURITY PROFILING AND DEGRADATION STUDY OF ALECTINIB	21
3.1. INTRODUCTION AND SELECTION OF DRUG	21
3.2 DRUG PROFILE	22
3.3 LITERATURE REVIEW	23
3.4 SECTION –A ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF ALECTINIB IN PRESENCE OF ITS DEGRADATION PRODUCTS BY HPLC. EXPERIMENTAL RESULTS AND DISCUSSION	24
3.5. SECTION –B DEGRADATION KINETIC STUDY OF ALECTINIB BY HPLC METHOD EXPERIMENTAL RESULTS AND DISCUSSION	55
3.6 SECTION-C ISOLATION AND CHARACTERIZATION OF MAJOR DEGRADATION PRODUCTS OF ALECTINIB RESULTS AND DISCUSSION	60
3.7 CONCLUSION	115
3.8 SECTION-D Quantitative estimation and validation of alectinib hydrochloride drug substance using quantitative nuclear magnetic resonance spectroscopy EXPERIMENTAL RESULTS AND DISCUSSION CONCLUSION	116
3.9 REFERENCES	127

CHAPTER 4: IMPURITY PROFILING AND DEGRADATION STUDY OF NELARABINE	132
4.1. INTRODUCTION AND SELECTION OF DRUG	132
4.2 DRUG PROFILE	132
4.3 LITERATURE REVIEW	133
4.4 SECTION –A ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF NELARABINE IN PRESENCE OF ITS DEGRADATION PRODUCTS BY HPLC. EXPERIMENTAL RESULTS AND DISCUSSION	134
4.5. SECTION –B DEGRADATION KINETIC STUDY OF NELARABINE BY HPLC METHOD EXPERIMENTAL RESULTS AND DISCUSSION	159
4.6 SECTION-C ISOLATION AND CHARACTERIZATION OF MAJOR DEGRADATION PRODUCTS OF NELARABINE RESULTS AND DISCUSSION	166
4.7 CONCLUSION	195
4.8 REFERENCES	196
CHAPTER 5: IMPURITY PROFILING AND DEGRADATION STUDY OF GIMERACIL	200
5.1. INTRODUCTION AND SELECTION OF DRUG	200
5.2 DRUG PROFILE	201
5.3 LITERATURE REVIEW	201

5.4 SECTION –A ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF GIMERACIL IN PRESENCE OF ITS DEGRADATION PRODUCTS BY HPLC AND LC-MS EXPERIMENTAL RESULTS AND DISCUSSION	202
5.5 SECTION-B CHARACTERIZATION OF MAJOR DEGRADATION PRODUCTS OF GIMERACIL	233
5.5 CONCLUSION	259
5.6 REFERENCES	260
CHAPTER 6: SUMMARY AND CONCLUSION	262